Nevertheless, the distinct PP2A inactivating mechanisms between type I and type II ECs, as well as other gynecologic cancers, open up specific opportunities for direct or indirect, personalized therapeutic targeting of PP2A, in order to (re)-activate this phosphatase. The gene discussed is PTPA; the disease is female reproductive organ cancer.